바이오리더스

KR EN

History

이전 버튼 다음버튼

MOAlifeplus’s leap
forward in a healthy world

As a global healthcare group, MOAlifeplus will step towards
the creation of a healthy and joyful world.

MOAlifeplus Leading Creative Innovation

Leap as a global
healthcare
corporation
2018.

03.Selected as a “High-Growth Company in the Asia-Pacific region” by the United Kingdom’s Financial Times

03.Took over the management rights of Next BT

2017.

02.DMD medicine [BLS-M22] designated as an orphan drug by United States’ FDA (ODD)

Accelerate
growth
2017.

12.Received the “Grand Prize” in the R&D category at the 2017 Korea SME Awards / Institute for IndustrialPolicy Studies

12.Selected as an “outstanding company R&D center” in the second half of 2017 / Ministry of Science & ICT

10.Launched the “She’s Ready”, a skincare brand

09.Relocated and installed a production line from Daejeon to National Food Cluster in Iksan, Jeollabuk-do

08.Started Clinical Phase 2b of the treatment vaccine for cervical cancer [BLS-M07]

07.Obtained the hygiene license from the China Food and Drug Administration (CFDA) for its cosmetics products,"Doctors PGA Moisture Mask Pack"

07.Signed for the "joint development of the next-generation of female cancer treatment vaccines"with CHA Bundang Medical Center

06.Completed a non-clinical toxicity test of DMD medicine [BLS-M22]

01.Signed an agreement for vaccine development with CHA Vaccine Institute

2016.

12.Received the “Excellence Prize” at the 13th Korea New Growth Management Awards / Ministry of Trade,Industry and Energy

10.Selected as a K-Brain Power company of 2016 / Institute for Industrial Policy Studies

09.Merged and relocated Suji Headquarters, Gyeonggi-do

07.Listed on KOSDAQ

Prepare foundation
for growth
2016.

12.Completed Clinical Phase 2b of CIN1 medicine [BLS-H01]

11.Clinical Phase 1 of CIN1 medicine [BLS-H01] approved (Ministry of Food and Drug Safety)

11.Listed on KONEX

03.Completed Clinical Phase 2a of the treatment vaccine for cervical cancer [BLS-M07]

Secure R&D
competitiveness
2008.

07.Established Japan Office (Osaka)

2007.

12.Selected as one of Korea's Top 10 New Technologies and received the Technology Award for <Mass-production Manufacturing Technology for Poly-γ-glutamic Acid with Extremely High Molecular Weight> / Ministry of Trade,Industry and Energy

08.Acquired "NET", a new technology certification <Medicine Material Development Technology Using HighMolecular Weight Poly-γ-glutamic Acid> / Korea Industrial Technology Association

Establish business
foundation
2005.

12.Attracted investment from and signed a joint technology development contract with Green Cross Corp.

2001.

08.Selected as an INNO-BIZ (Grade Aa) / Ministry of SMEs and Startups

2000.

07.Recognized as a company affiliate research center / Korea Industrial Technology Association

07.Founded BioLeaders Co., Ltd.